Journal article Open Access

Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence‐Based Review by the United States Food and Drug Administration

Trumbo PhD, Paula R.; Ellwood, Kathleen C.


Citation Style Language JSON Export

{
  "DOI": "10.1111/j.1753-4887.2006.tb00220.x", 
  "author": [
    {
      "family": "Trumbo PhD, Paula R."
    }, 
    {
      "family": "Ellwood, Kathleen C."
    }
  ], 
  "issued": {
    "date-parts": [
      [
        2008, 
        6, 
        27
      ]
    ]
  }, 
  "abstract": "The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.", 
  "title": "Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence\u2010Based Review by the United States Food and Drug Administration", 
  "type": "article-journal", 
  "id": "1230786"
}
238
210
views
downloads
Views 238
Downloads 210
Data volume 15.2 MB
Unique views 236
Unique downloads 204

Share

Cite as